BioLineRx Reports Year End 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
BioLineRx (BLRX) PT Lowered to $2 at Maxim Group
March 6, 2018 1:21 PM ESTMaxim Group lowered its price target on BioLineRx (NASDAQ: BLRX) to $2.00 (from $3.00) while maintaining a Buy rating.
Analyst Jason McCarthy commented, "BiolineRx reported 4Q17 with a net loss of $7.4M and ended the period with $50M in cash on the balance sheet,... More
